Additional file 1: Figure S1. of One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond DayonLoïc GuiraudSeu CorthésyJohn SilvaLaeticia Da MigliavaccaEugenia TautvydaitėDomilė OikonomidiAikaterini MoulletBarbara HenryHugues MétaironSylviane MarquisJulien DescombesPatrick CollinoSebastiano MartinFrançois-Pierre MontoliuIvan KussmannMartin WojcikJérôme BowmanGene PoppJulius 2017 Box plots of CSF metabolite measurements for CDR of 0 and CDR >0 (i.e., CDR 0.5 or 1). Level of significance is indicated as p value after Bonferroni correction. Values were log-transformed. Figure S2. Box plots of plasma metabolite measurements for CDR 0 and CDR >0 (i.e., CDR 0.5 or 1). Level of significance is indicated as p value after Bonferroni correction. Concentration values were log-transformed. Figure S3. CSF and plasma metabolites correlated with CSF p-tau181 (a) and CSF tau (b) in APOE ε4 carriers (n = 37). Concentration values were log-transformed. Each dot represents a subject. The black line represents the linear fit, and the gray shading represents its confidence interval. Figure S4. Box plots of plasma metabolite measurements in APOE ε4 carriers (n = 37) according to CSF p-tau181/Aβ1–42 ratio (i.e., “low” when p-tau181/Aβ1–42 is ≤0.0779 and “high” when p-tau181/Aβ1–42 is > 0.0779) for negative and positive CSF profiles of AD pathology, respectively. Concentration values were log10-transformed. Level of significance is indicated as p value after Bonferroni correction. Supplementary Methods. (PDF 831 kb)